TREATMENT OF CANCER WITH COMBINATIONS OF IMMUNOREGULATORY AGENTS
Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of immunoregulatory agents. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Europäisches Patentamt - (2021) vom: 29. Juli Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
WILLINGHAM STEPHEN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-07-29, Last update posted on www.tib.eu: 2024-02-23, Last updated: 2024-03-01 |
|---|
| Patentnummer: |
US2021230276 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA015628094 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA015628094 | ||
| 003 | DE-627 | ||
| 005 | 20240301101612.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230216s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA015628094 | ||
| 035 | |a (EPA)US2021230276 | ||
| 035 | |a (EPA)59360269 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a WILLINGHAM STEPHEN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a TREATMENT OF CANCER WITH COMBINATIONS OF IMMUNOREGULATORY AGENTS |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2021-07-29, Last update posted on www.tib.eu: 2024-02-23, Last updated: 2024-03-01 | ||
| 520 | |a Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of immunoregulatory agents. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a HO DORIS PO YI |4 aut | |
| 700 | 0 | |a MCKENNA KELLY MARIE |4 aut | |
| 700 | 0 | |a WEISSMAN IRVING L |4 aut | |
| 700 | 0 | |a VOLKMER JENS-PETER |4 aut | |
| 700 | 0 | |a CHAO MARK P |4 aut | |
| 700 | 0 | |a MAJETI RAVINDRA |4 aut | |
| 700 | 0 | |a MCCRACKEN MELISSA N |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 29. Juli |
| 773 | 1 | 8 | |g year:2021 |g day:29 |g month:07 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/59360269/publication/US2021230276A1?q=US2021230276 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 29 |c 07 | ||